Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PcTx-1** (psalmotoxin 1) is a 40-amino acid peptide toxin derived from the venom of the Trinidad tarantula *Psalmopoeus cambridgei*. It is a member of the inhibitor cystine knot (ICK) peptide family, featuring three disulfide bonds stabilizing a compact structure comprised mainly of a three-stranded antiparallel β-sheet and multiple loops. PcTx-1 is the first identified and most potent **selective blocker** of the acid-sensing ion channel 1a (**ASIC1a**), a proton-gated sodium channel implicated in pain perception (nociception), synaptic plasticity, learning, and memory. PcTx-1 binds to the extracellular domain of ASIC1a, increasing its apparent affinity for protons and thereby inducing chronic desensitization at physiological pH. This mechanism effectively inhibits ASIC1a activity, with potential analgesic and neuroprotective effects shown in preclinical rodent models of acute pain and ischemic stroke. PcTx-1 blocks ASIC1a with high potency (IC50 in the low nanomolar range) and selectivity, and its unique binding surface provides a template for the development of future ASIC-targeted therapeutics[1][5][3][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pctx-1.